A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

~56 mi. (Nizhniy Novgorod, Russia, +144 more cities)

Nizhniy Novgorod Region Oncology Dispensary ( Site 2621)

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

~56 mi. (Nizhniy Novgorod, Russia, +176 more cities)

Nizhegorodsky Regional Oncology Dispensary-chemotherapy department (Branch№1) ( Site 2639)

Endometrial Carcinoma, +1 more condition

chemotherapy, +2 more drugs

chemotherapy, +2 more types

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

~56 mi. (Nizhniy Novgorod, Russia, +89 more cities)

Nizhegorodsky Regional Oncology Dispensary-chemotherapy ( Site 1912)

ER Positive, +2 more biomarkers

Breast Carcinoma

capecitabine, +4 more drugs

chemotherapy, +1 more type

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

~56 mi. (Nizhniy Novgorod, Russia, +383 more cities)

Nizhny Novgorod Regional Clinical Oncology Center

ER Negative, +2 more biomarkers

Breast Carcinoma

atezolizumab, +4 more drugs

chemotherapy, +1 more type

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

~56 mi. (Nizhniy Novgorod, Russia, +93 more cities)

Volga District Medical Center ( Site 0876)

Bladder Carcinoma, +1 more condition

cisplatin, +4 more drugs

chemotherapy, +3 more types

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

~56 mi. (Nizhniy Novgorod, Russia, +159 more cities)

Volga District Medical Center Federal Medical and Biological Agency ( Site 0857)

Superficial Bladder Urothelial Carcinoma

cisplatin, +2 more drugs

chemotherapy, +1 more type

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

~56 mi. (Nizhniy Novgorod, Russia, +163 more cities)

Volga District Medical Center Federal Medical and Biological Agency ( Site 0857)

Bladder Urothelial Carcinoma

cystectomy, +2 more drugs

chemotherapy, +3 more types

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

~56 mi. (Nizhniy Novgorod, Russia, +158 more cities)

Nizhniy Novgorod Region Oncology Dispensary ( Site 1914)

Non-Small Cell Lung Carcinoma

olaparib, +4 more drugs

chemotherapy, +3 more types

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

~56 mi. (Nizhniy Novgorod, Russia, +260 more cities)

Nizhny Novgorod Regional Clinical Oncology Center

ERBB2 Amplification, +1 more biomarker

Invasive Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

immunotherapy, +1 more type

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003)

~56 mi. (Nizhniy Novgorod, Russia, +93 more cities)

Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 0809)

PD-L1 High Expression (TPS >= 1%), +1 more biomarker

Non-Small Cell Lung Carcinoma

vibostolimab/pembrolizumab MK-7684A

immunotherapy

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

~56 mi. (Nizhniy Novgorod, Russia, +122 more cities)

Nizhniy Novgorod Region Oncology Dispensary ( Site 1811)

Small Cell Lung Carcinoma

etoposide, +5 more drugs

chemotherapy, +3 more types

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

~56 mi. (Nizhniy Novgorod, Russia, +137 more cities)

Nizhniy Novgorod regional clinical oncological dispensary ( Site 1169)

Skin Squamous Cell Carcinoma

pembrolizumab

immunotherapy